San Diego-based ViaCyte, a company which is using stem cell technology to develop treatments for Type 1 Diabetes, says it has raised $45M in an extension of its Series D funding round. The funding brings its Series D funding to more than $115M. The funding came from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, plus new investors Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures. The company said the funding will be used to fund the most advanced portfolio of stem cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. ViaCyte is led by President and CEO Michael Yang.